All In Biotech

NDA 022496 · Pacira Pharms INC

Exparel

Bupivacaine · Injection · Amide Local Anesthetic

Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Oct 28, 2011

Approved uses

4

Original approval plus efficacy supplements

Registered trials

2,836

341 Phase 3, 228 recruiting

FAERS reports

9,403

7,042 serious, 592 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 9, 2026.

EXPAREL is indicated to produce postsurgical: Local analgesia via infiltration in patients aged 6 years and older Regional analgesia via an interscalene brachial plexus nerve block in adults Regional analgesia via a sciatic nerve block in the popliteal fossa in adults Regional analgesia via an adductor canal block in adults EXPAREL contains bupivacaine, an amide local anesthetic, and is indicated to produce postsurgical: Local analgesia via infiltration in patients aged 6 years and older ( 1 ). Regional analgesia via an interscalene brachial plexus nerve block in adults ( 1 ). Regional analgesia via a sciatic nerve block in the popliteal fossa in adults ( 1 ). Regional analgesia via an adductor canal block in adults ( 1 ). Limitations of Use The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. Limitations of Use The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block.

Mechanism: Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • EXPAREL · BUPIVACAINE 266MG/20ML (13.3MG/ML) · INJECTABLE, LIPOSOMAL, INJECTION · Prescription · TE AP
  • EXPAREL · BUPIVACAINE 133MG/10ML (13.3MG/ML) · INJECTABLE, LIPOSOMAL, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.

All 2,836 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use905
  • pain772
  • drug ineffective736
  • hypotension548
  • nausea414
  • hypoaesthesia381
  • maternal exposure during pregnancy379
  • exposure during pregnancy336
  • drug withdrawal syndrome281
  • vomiting275
  • maternal exposure during delivery258
  • labelled drug-drug interaction medication error250

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004182
2005132
2006187
2007152
2008206
2009224
20106
201111
2012135
2013394
2014398
2015294
2016614
2017657
2018646
2019772
2020912
2021631
2022683
2023675
2024543
2025648
2026301

Recalls

1 FDA enforcement reports for this application.

  • Nov 21, 2019 · Class II · Terminated

    Sub Potent Drug: Out of Specification (OOS)

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5,897 on PubMed

Sponsor: Pacira Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.